MedTech Industry Dynamics
MedTech Industry Dynamics
In vitro diagnostics (IVD) are tests done on samples such as blood or tissue that have been taken from the human body. In vitro diagnostics can detect diseases or other conditions, and can be used to monitor a person’s overall health to help cure, treat, or prevent diseases.
In vitro diagnostics may also be used in precision medicine to identify patients who are likely to benefit from specific treatments or therapies. These in vitro diagnostics can include next generation sequencing tests, which scan a person’s DNA to detect genomic variations.
Some tests are used in laboratory or other health professional settings and other tests are for consumers to use at home.
QIAGEN has launched QIAsymphony Connect, an IVD-compliant automated platform for clinical nucleic acid extraction that builds on more than 3,300 cumulative placements of the established QIAsymphony platform while using the same reagent kits and consumables.
Lire la suiteQIAGEN has appointed Jonathan M. Pratt as Chief Executive Officer, who brings more than 25 years of leadership experience across life sciences and laboratory technologies, including serving as CEO of Filtration Group and president of Beckman Coulter Life Sciences.
Lire la suiteRoche has received FDA clearance for its Elecsys pTau217 blood test, the first and only FDA-cleared single-biomarker test supporting both rule-in and rule-out assessment of amyloid pathology. Quest Diagnostics and Labcorp will offer the test to clinicians nationwide.
Lire la suiteC2N Diagnostics has received FDA clearance for its PrecivityAD2 blood test, the first Alzheimer’s diagnostic aid cleared for use in symptomatic adults aged 40 and older, delivering high diagnostic performance to help clinicians rule in or rule out clinical Alzheimer’s disease.
Lire la suiteDanaher has appointed Julie Sawyer Montgomery as President and Chief Executive Officer, effective October 1, 2026, succeeding Rainer Blair, who will retire and serve as senior advisor until March 2027.
Lire la suiteBeckman Coulter Diagnostics a lancé le système DxU 1800, une solution d’analyse d’urine entièrement automatisée combinant un nouvel analyseur de chimie avec une technologie de microscopie éprouvée, conçue pour aider les laboratoires à répondre à des volumes de tests croissants et à fournir des résultats standardisés à grande échelle.
Lire la suiteTempus has entered into a definitive agreement to acquire Personalis for $1.5 billion, integrating the company’s ultrasensitive minimal residual disease (MRD) technology into Tempus’ AI-enabled precision oncology platform to advance cancer monitoring and biomarker discovery.
Lire la suiteLeica Biosystems a conclu un accord définitif pour acquérir StatLab Medical Products, un développeur de premier plan de produits d’anatomopathologie, auprès de Linden Capital Partners et Audax Private Equity, élargissant ainsi son offre d’histologie pré-analytique et analytique.
Lire la suiteAmprion and Modality.AI have announced a collaboration to combine molecular biomarkers with AI-enabled digital assessments, aiming to improve characterization and monitoring of neurodegenerative diseases including Parkinson’s and ALS.
Lire la suiteBeckman Coulter Diagnostics has received CE Mark under IVDR for its Access p-Tau217 blood test to support clinical evaluation of amyloid pathology in cognitive decline, while also launching a high-specificity brain-derived pTau217 research assay for neurodegenerative research.
Lire la suite
